Viking Therapeutics experienced a surge in stock value due to promising obesity data ahead of a significant capital raise. In contrast, Longeveron faced a decline following a mid-stage trial setback, raising concerns about its future prospects.
Viking Therapeutics rode strong obesity data before a major capital raise, while Longeveron’s mid-stage setback prompted questions about its future.
Original title: “Significant stock movers of September: Viking soars, Longeveron slides”